{"transactions":[{"id":1951145,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":115497,"kind":"person","name":"Beyer Russell P","position":1,"cik":"0001889754","reported_name":"Beyer Russell P","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-16T20:27:20.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":275000,"derivative":{"exercise_price":0.54,"expiration_date":"2033-03-14","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0001437749-23-006908","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923006908/rdgdoc.xml","form_type":"4"}},{"id":2158875,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":115497,"kind":"person","name":"Beyer Russell P","position":1,"cik":"0001889754","reported_name":"Beyer Russell P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-09-15T20:45:16.000Z","date":"2022-09-13","kind":"grant","acquired":true,"shares":274875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining\n3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":274875,"derivative":{"exercise_price":0.71,"expiration_date":"2032-09-13","underlying":"Common Stock","underlying_shares":274875},"source":{"system":"sec-edgar","filing":"0001209191-22-050081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000120919122050081/doc4.xml","form_type":"4"}},{"id":2325551,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":115497,"kind":"person","name":"Beyer Russell P","position":1,"cik":"0001889754","reported_name":"Beyer Russell P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-03-19T01:15:51.000Z","date":"2022-03-16","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors."}],"balance_after":6000,"derivative":{"exercise_price":1.78,"expiration_date":"2032-03-16","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-22-011666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000089924322011666/doc4.xml","form_type":"4"}},{"id":2503719,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":115497,"kind":"person","name":"Beyer Russell P","position":1,"cik":"0001889754","reported_name":"Beyer Russell P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-11-19T21:45:07.000Z","date":"2021-11-17","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock granted to the Reporting Person pursuant to the Company's 2021 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter."}],"balance_after":110000,"derivative":{"exercise_price":11.17,"expiration_date":"2031-11-17","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001493152-21-029395","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221029395/ownership.xml","form_type":"4"}},{"id":2511863,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":115497,"kind":"person","name":"Beyer Russell P","position":1,"cik":"0001889754","reported_name":"Beyer Russell P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-16T20:09:58.000Z","date":"2021-09-29","kind":"grant","acquired":true,"shares":10,"price":10.08,"value":100.8,"ownership":{"direct":false,"nature":"By daughter"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Issuer\"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination."}],"balance_after":15,"source":{"system":"sec-edgar","filing":"0001493152-21-028917","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221028917/ownership.xml","form_type":"4"}},{"id":2511862,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":115497,"kind":"person","name":"Beyer Russell P","position":1,"cik":"0001889754","reported_name":"Beyer Russell P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-16T20:09:58.000Z","date":"2021-09-28","kind":"grant","acquired":true,"shares":5,"price":10.07,"value":50.35,"ownership":{"direct":false,"nature":"By daughter"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Issuer\"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination."}],"balance_after":5,"source":{"system":"sec-edgar","filing":"0001493152-21-028917","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221028917/ownership.xml","form_type":"4"}},{"id":2511861,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":115497,"kind":"person","name":"Beyer Russell P","position":1,"cik":"0001889754","reported_name":"Beyer Russell P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-16T20:09:58.000Z","date":"2021-10-26","kind":"sale","acquired":false,"shares":278,"price":7.9,"value":2196.2,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale of Issuer common stock by the reporting person's spouse reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 278 shares, with the purchase of 278 shares of Issuer's common stock as also reported herein. The reporting person has paid to Issuer, upon settlement of the sale, $15.48, representing the full amount of the profit realized in connection with the short-swing transaction."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001493152-21-028917","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221028917/ownership.xml","form_type":"4"}},{"id":2511860,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":115497,"kind":"person","name":"Beyer Russell P","position":1,"cik":"0001889754","reported_name":"Beyer Russell P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-16T20:09:58.000Z","date":"2021-10-25","kind":"grant","acquired":true,"shares":129,"price":7.78,"value":1003.62,"ownership":{"direct":false,"nature":"By spouse"},"balance_after":278,"source":{"system":"sec-edgar","filing":"0001493152-21-028917","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221028917/ownership.xml","form_type":"4"}},{"id":2511859,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":115497,"kind":"person","name":"Beyer Russell P","position":1,"cik":"0001889754","reported_name":"Beyer Russell P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-16T20:09:58.000Z","date":"2021-09-28","kind":"grant","acquired":true,"shares":149,"price":10.08,"value":1501.92,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Issuer\"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination."}],"balance_after":149,"source":{"system":"sec-edgar","filing":"0001493152-21-028917","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221028917/ownership.xml","form_type":"4"}},{"id":2511858,"issuer":{"id":5816,"kind":"organization","name":"SAB Biotherapeutics, Inc.","symbol":"SABS"},"owners":[{"id":115497,"kind":"person","name":"Beyer Russell P","position":1,"cik":"0001889754","reported_name":"Beyer Russell P","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-16T20:09:58.000Z","date":"2021-10-18","kind":"grant","acquired":true,"shares":2475,"price":10.1,"value":24997.5,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. (\"Issuer\"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination."}],"balance_after":2475,"source":{"system":"sec-edgar","filing":"0001493152-21-028917","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833214/000149315221028917/ownership.xml","form_type":"4"}}]}